Alnylam Pharmaceuticals Inc (ALNY)vsRoyalty Pharma Plc (RPRX)
ALNY
Alnylam Pharmaceuticals Inc
$205.52
+0.02%
HEALTHCARE · Cap: $27.50B
RPRX
Royalty Pharma Plc
$58.43
-1.00%
HEALTHCARE · Cap: $33.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 97% more annual revenue ($4.80B vs $2.44B). RPRX leads profitability with a 33.9% profit margin vs 16.0%. ALNY appears more attractively valued with a PEG of 0.37. ALNY earns a higher WallStSmart Score of 68/100 (B-).
ALNY
Strong Buy68
out of 100
Grade: B-
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.7%
Fair Value
$2613.72
Current Price
$205.52
$2408.20 discount
Margin of Safety
-66.8%
Fair Value
$35.03
Current Price
$58.43
$23.40 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 66.9% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Elevated debt levels
Trading at 20.3x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Profitability is solid with margins at 16.0% and operating margin at 17.9%. Revenue growth of 66.9% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are P/E Ratio, EPS Growth, Debt/Equity.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ALNY profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
ALNY is growing revenue faster at 66.9% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (68/100 vs 65/100), backed by strong 16.0% margins and 66.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?